Ascendis Pharma ADR

Ascendis is presenting 104-week data from the ApproaCH study of once-weekly TransCon CNP (YUVIWEL) in children with achondroplasia at the annual meeting of the International Skeletal Dysplasia Society, including data from the open-label extension. YUVIWEL received FDA approval in February 2026 for pediatric patients aged two years and older; an EMA decision is expected in Q4 2026. Ascendis is also showing a poster on injection site reactions when an indirect treatment comparison is not possible. » More on de.investing.com

Ascendis publishes five‑year Phase‑2 data for TransCon PTH (YORVIPATH) showing sustained efficacy and tolerability in adults with hypoparathyroidism. At week 266, 82% of patients met a composite endpoint (normal serum calcium, no active vitamin D, <600 mg calcium/day); 96% were independent of active vitamin D and 95% were able to stop therapeutic calcium supplements. Kidney function improved, 24‑hour urine calcium normalized within 26 weeks and remained stable; adverse events were mostly mild to moderate, with no study‑related discontinuations. The clinical results support the company’s commercial momentum (revenue LTM $1 billion, gross margin 89%) and bolster analysts’ expectations for sustained profitability. » More on de.investing.com

The board of directors of Ascendis Pharma issued 27,030 options to certain employees, each entitling the holder to one common share at an exercise price of USD 213.23, the closing price on the grant date. 25% of the options vest after one year, with the remaining 75% vesting over the following three years in equal monthly instalments, subject to continued employment. Vesting may accelerate upon certain exit events. Under the plan, options to acquire 1,553,563 shares remain available for future grants. » More on de.investing.com